Literature DB >> 15557633

Adaptation of the endogenous Salmonella enterica serovar Typhi clyA-encoded hemolysin for antigen export enhances the immunogenicity of anthrax protective antigen domain 4 expressed by the attenuated live-vector vaccine strain CVD 908-htrA.

James E Galen1, Licheng Zhao, Magaly Chinchilla, Jin Yuan Wang, Marcela F Pasetti, Jeffrey Green, Myron M Levine.   

Abstract

Bacterial live-vector vaccines aim to deliver foreign antigens to the immune system and induce protective immune responses, and surface-expressed or secreted antigens are generally more immunogenic than cytoplasmic constructs. We hypothesize that an optimum expression system will use an endogenous export system to avoid the need for large amounts of heterologous DNA encoding additional proteins. Here we describe the cryptic chromosomally encoded 34-kDa cytolysin A hemolysin of Salmonella enterica serovar Typhi (ClyA) as a novel export system for the expression of heterologous antigens in the supernatant of attenuated Salmonella serovar Typhi live-vector vaccine strains. We constructed a genetic fusion of ClyA to the reporter green fluorescent protein and showed that in Salmonella serovar Typhi CVD 908-htrA, the fusion protein retains biological activity in both domains and is exported into the supernatant of an exponentially growing live vector in the absence of detectable bacterial lysis. The utility of ClyA for enhancing the immunogenicity of an otherwise problematic antigen was demonstrated by engineering ClyA fused to the domain 4 (D4) moiety of Bacillus anthracis protective antigen (PA). A total of 11 of 15 mice immunized intranasally with Salmonella serovar Typhi exporting the protein fusion manifested fourfold or greater rises in serum anti-PA immunoglobulin G, compared with only 1 of 16 mice immunized with the live vector expressing cytoplasmic D4 (P = 0.0002). In addition, the induction of PA-specific gamma interferon and interleukin 5 responses was observed in splenocytes. This technology offers exceptional versatility for enhancing the immunogenicity of bacterial live-vector vaccines.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15557633      PMCID: PMC529119          DOI: 10.1128/IAI.72.12.7096-7106.2004

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  53 in total

1.  Optimization of plasmid maintenance in the attenuated live vector vaccine strain Salmonella typhi CVD 908-htrA.

Authors:  J E Galen; J Nair; J Y Wang; S S Wasserman; M K Tanner; M B Sztein; M M Levine
Journal:  Infect Immun       Date:  1999-12       Impact factor: 3.441

2.  Vesicle-mediated export and assembly of pore-forming oligomers of the enterobacterial ClyA cytotoxin.

Authors:  Sun Nyunt Wai; Barbro Lindmark; Tomas Söderblom; Akemi Takade; Marie Westermark; Jan Oscarsson; Jana Jass; Agneta Richter-Dahlfors; Yoshimitsu Mizunoe; Bernt Eric Uhlin
Journal:  Cell       Date:  2003-10-03       Impact factor: 41.582

3.  Anthrax vaccine: immunogenicity and safety of a dose-reduction, route-change comparison study in humans.

Authors:  Phillip R Pittman; Gina Kim-Ahn; Dominique Y Pifat; Kevin Coonan; Paul Gibbs; Steve Little; Judith G Pace-Templeton; Robert Myers; Gerald W Parker; Arthur M Friedlander
Journal:  Vaccine       Date:  2002-01-31       Impact factor: 3.641

4.  A murine model of intranasal immunization to assess the immunogenicity of attenuated Salmonella typhi live vector vaccines in stimulating serum antibody responses to expressed foreign antigens.

Authors:  J E Galen; O G Gomez-Duarte; G A Losonsky; J L Halpern; C S Lauderbaugh; S Kaintuck; M K Reymann; M M Levine
Journal:  Vaccine       Date:  1997 Apr-May       Impact factor: 3.641

5.  Role of toxin functional domains in anthrax pathogenesis.

Authors:  F Brossier; M Weber-Levy; M Mock; J C Sirard
Journal:  Infect Immun       Date:  2000-04       Impact factor: 3.441

6.  Attenuated deltaguaBA Salmonella typhi vaccine strain CVD 915 as a live vector utilizing prokaryotic or eukaryotic expression systems to deliver foreign antigens and elicit immune responses.

Authors:  M F Pasetti; R J Anderson; F R Noriega; M M Levine; M B Sztein
Journal:  Clin Immunol       Date:  1999-07       Impact factor: 3.969

7.  Superior efficacy of secreted over somatic antigen display in recombinant Salmonella vaccine induced protection against listeriosis.

Authors:  J Hess; I Gentschev; D Miko; M Welzel; C Ladel; W Goebel; S H Kaufmann
Journal:  Proc Natl Acad Sci U S A       Date:  1996-02-20       Impact factor: 11.205

8.  Comparative efficacy of experimental anthrax vaccine candidates against inhalation anthrax in rhesus macaques.

Authors:  B E Ivins; M L Pitt; P F Fellows; J W Farchaus; G E Benner; D M Waag; S F Little; G W Anderson; P H Gibbs; A M Friedlander
Journal:  Vaccine       Date:  1998-07       Impact factor: 3.641

9.  Salmonella enterica serovar Typhi live vector vaccines delivered intranasally elicit regional and systemic specific CD8+ major histocompatibility class I-restricted cytotoxic T lymphocytes.

Authors:  Marcela F Pasetti; Rosangela Salerno-Gonçalves; Marcelo B Sztein
Journal:  Infect Immun       Date:  2002-08       Impact factor: 3.441

10.  Bacillus anthracis protective antigen, expressed in Salmonella typhimurium SL 3261, affords protection against anthrax spore challenge.

Authors:  N M Coulson; M Fulop; R W Titball
Journal:  Vaccine       Date:  1994-11       Impact factor: 3.641

View more
  32 in total

1.  Systemic and Mucosal Immune Responses to Cryptosporidium-Vaccine Development.

Authors:  Jacob G Ludington; Honorine D Ward
Journal:  Curr Trop Med Rep       Date:  2015-09-01

2.  Engineered bacterial outer membrane vesicles with enhanced functionality.

Authors:  Jae-Young Kim; Anne M Doody; David J Chen; Gina H Cremona; Michael L Shuler; David Putnam; Matthew P DeLisa
Journal:  J Mol Biol       Date:  2008-04-09       Impact factor: 5.469

3.  Towards a human oral vaccine for anthrax: the utility of a Salmonella Typhi Ty21a-based prime-boost immunization strategy.

Authors:  Leslie W J Baillie; Ana L Rodriguez; Stephen Moore; Helen S Atkins; Chiguang Feng; James P Nataro; Marcela F Pasetti
Journal:  Vaccine       Date:  2008-09-19       Impact factor: 3.641

4.  Delivery of foreign antigens by engineered outer membrane vesicle vaccines.

Authors:  David J Chen; Nikolaus Osterrieder; Stephan M Metzger; Elizabeth Buckles; Anne M Doody; Matthew P DeLisa; David Putnam
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-27       Impact factor: 11.205

Review 5.  New technologies in developing recombinant attenuated Salmonella vaccine vectors.

Authors:  Shifeng Wang; Qingke Kong; Roy Curtiss
Journal:  Microb Pathog       Date:  2012-11-08       Impact factor: 3.738

Review 6.  Microgravity as a biological tool to examine host-pathogen interactions and to guide development of therapeutics and preventatives that target pathogenic bacteria.

Authors:  Ellen E Higginson; James E Galen; Myron M Levine; Sharon M Tennant
Journal:  Pathog Dis       Date:  2016-09-13       Impact factor: 3.166

7.  Anthrax protective antigen delivered by Salmonella enterica serovar Typhi Ty21a protects mice from a lethal anthrax spore challenge.

Authors:  Manuel Osorio; Yanping Wu; Sunil Singh; Tod J Merkel; Siba Bhattacharyya; Milan S Blake; Dennis J Kopecko
Journal:  Infect Immun       Date:  2009-01-29       Impact factor: 3.441

8.  Use of mchI encoding immunity to the antimicrobial peptide microcin H47 as a plasmid selection marker in attenuated bacterial live vectors.

Authors:  Chee-Mun Fang; Jin Yuan Wang; Magaly Chinchilla; Myron M Levine; William C Blackwelder; James E Galen
Journal:  Infect Immun       Date:  2008-07-28       Impact factor: 3.441

9.  A new generation of stable, nonantibiotic, low-copy-number plasmids improves immune responses to foreign antigens in Salmonella enterica serovar Typhi live vectors.

Authors:  James E Galen; Jin Yuan Wang; Magaly Chinchilla; Christopher Vindurampulle; Jeffrey E Vogel; Haim Levy; William C Blackwelder; Marcela F Pasetti; Myron M Levine
Journal:  Infect Immun       Date:  2009-11-02       Impact factor: 3.441

10.  Mucosal immunization with attenuated Salmonella enterica serovar Typhi expressing protective antigen of anthrax toxin (PA83) primes monkeys for accelerated serum antibody responses to parenteral PA83 vaccine.

Authors:  James E Galen; Magaly Chinchilla; Marcela F Pasetti; Jin Yuan Wang; Licheng Zhao; Ivonne Arciniega-Martinez; David J Silverman; Myron M Levine
Journal:  J Infect Dis       Date:  2009-02-01       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.